There is a new treatment for skin cancer, which causes huge amounts of money. Big enough for two large pharmaceutical companies, GlaxoSmithKline PLC and Synta Pharmaceuticals Corporation together to develop an interesting and very promising new treatment for skin cancer drug. This drug has been shown that even at 1V melanoma, 70 percent of victims die within a year of aid
Named the STA-4783, which is a new, injectable> Candidate drug that kills cancer cells by overloading cancer cells with oxygen. Because cancer cells do not themselves have a much lower tolerance for oxygen-malignant cells, which leads to self-destruction. This is a new class of anti-cancer therapy, with considerable potential.
Put simply, STA-4783 increases the level of oxygen within the tumor cells. Cancer cells can not tolerate as much oxygen as normal cells, and this drug increases the oxygen content in tumor cells,and this causes the cell to move with the critical point of baking, then undergo apoptosis or programmed cell death. STA has little or no effect on normal non-cancerous cells.
The fact that such a strategy against cancer in healthy and diseased cells can distinguish cancer cells alone, is why scientists are so enthusiastic and we are confident that this treatment will be successful in treating a variety of tumors,
In a double blind study found thatSTA-4783, when used in small doses with Taxol (paclitaxel or) will be twice the rate of progression-free survival in stage 1V melanoma compared with Taxol long.
Melanoma is a very deadly skin cancer once it has spread to his last place of origin. At 1V melanoma, the cancer has spread throughout the body, and the survival of people with Stage 1V melanoma metastic is 7-10 months. Since there are only a few drugs that are useful for patients with advanced skin cancer, it is an importantBreakthrough.
